Flavii Therapeutics
Startup
-
Location
Hall 8.1 - 4YFN Stand 8.1C23.3B
Information
Flavii Therapeutics S.L. is a biotechnology company developing epigenetic therapies for central nervous system (CNS) disorders with high unmet medical need. Flavii lead program, FLVA-27, is a first-in-class small-molecule and an inhibitor of G9a, a key epigenetic regulator of brain function. FLAV-27 shows strong brain penetration, favorable PK/PD properties, and a robust safety profile. Preclinical studies support its neuroprotective effects and functional improvements across multiple CNS disease models (e.g. Alzheimer disease and Huntington disease). Flavii is advancing FLAV-27 toward clinical development to deliver disease-modifying therapies and bringing new hope to patients and families affected by these conditions.
Key Information
-
Pre-Seed
Growth Stage
-
CountrySpain
-
Founding Year2025